INTERACTIONS BETWEEN THE Ca^{2+}-SENSITISING LEVOSIMENDAN AND THE MYOCARDIAL β-ADRENERGIC SIGNAL TRANSDUCTION SYSTEM

Dr. Annamária Bódi

UNIVERSITY OF DEBRECEN

MEDICAL AND HEALTH SCIENCE CENTER

FACULTY OF MEDICINE

INSTITUTE OF CARDIOLOGY

DEBRECEN, 2004

Ph.D. Theses

INTERACTIONS BETWEEN THE Ca^{2+}-SENSITISING LEVOSIMENDAN AND THE MYOCARDIAL β-ADRENERGIC SIGNAL TRANSDUCTION SYSTEM

Dr. Annamária Bódi

Tutors: Dr. István Édes
Dr. Zoltán Papp

UNIVERSITY OF DEBRECEN

MEDICAL AND HEALTH SCIENCE CENTER

FACULTY OF MEDICINE

INSTITUTE OF CARDIOLOGY

DEBRECEN, 2004

INTRODUCTION

In the clinical practice, correction for the diminished contractile function of the failing myocardium is a major therapeutic challenge. Conventional positive inotropic agents increase the intracellular Ca^{2+} concentration ($[Ca^{2+}]_i$), and their application is therefore associated with adverse effects: an increased energy demand and arrhythmias. Pharmacological sensitisation of the contractile machinery to Ca^{2+} may alleviate these problems.

One of the most promising Ca^{2+}-sensitiser molecules is levosimendan, which proved effective in recent clinical trials. The pharmacological profile of levosimendan is complex, however, as it combines the potentials of Ca^{2+}-sensitisers and ATP-dependent K^+ channel openers. Accordingly, we set out to characterise the cardiac effects of levosimendan under various model conditions that either allowed or compromised the development of its dual major actions in the cardiovascular system. To this end, the contractile function of the myocardium was monitored in narcotised guinea pigs and in Langendorff-perfused hearts. The cardiac performance in narcotised guinea pigs is a function of the interaction between the contractile activity of the heart and the vascular system, and this arrangement therefore faithfully mimics *in vivo* conditions. In contrast, the cardiac loading was constant in the Langendorff preparations, and the cardiac effects of levosimendan could therefore be isolated from those depending on the preload and/or afterload. Finally, direct force measurement in single skinned cardiomyocytes allowed the analysis of the effects of levosimendan at the subcellular level.

Stimulation of the β-adrenergic signalling pathway involves an increase in the intracellular cyclic adenosine 3',-5'-monophosphate (cAMP) concentration and consequently in the level of protein phosphorylation through the activation of protein kinase A. In cardiac myocytes, protein kinase A phosphorylates the contractile proteins (including cardiac troponin I (cTnI) and myosin binding protein C), and hence decreases the Ca^{2+} sensitivity of force production. Thus, traditional β-mimetic positive inotropes may possibly interfere with the Ca^{2+}-sensitising mechanism of levosimendan. Indeed, Haikala et al. suggested that the phosphorylation of cTnI may

attenuate the positive inotropy induced by levosimendan. Surprisingly, however, it has recently been documented that isoproterenol pretreatment potentiates the contractile effects of levosimendan in isolated cardiac muscle strips from patients with dilated cardiomyopathy. Additionally, levosimendan, when applied at high concentrations, may inhibit intracellular phosphodiesterases, elevate the level of intracellular cyclic nucleotides, and therefore stimulate protein phosphorylation via protein kinases. In particular, the phosphorylation of phospholamban and the L-type Ca^{2+}-channel molecule would then interfere with the Ca^{2+} regulation of the contractile system.

In the present study, an attempt was made to reveal the possible interactions between the intracellular effects of β-adrenergic signalling and of levosimendan in the myocardium. This was achieved by comparing the contractile effects of levosimendan in guinea pigs before and after β-receptor stimulation (in narcotised animals and in Langendorff-perfused hearts) or after incubation with protein kinase A (in isolated skinned myocytes).

We report that the levosimendan-induced contractile effects were largely attenuated during intensive sympathetic stimulation, in parallel with the development of an increased level of intracellular phosphorylation. Hence, the benefit of the Ca^{2+}-sensitiser levosimendan may be negatively influenced by the simultaneous application of β-mimetic agents, an effect depending on the phosphorylation level of the contractile filaments.

AIMS

Investigations were performed using different animal models and a human clinical trial:

1) <u>Anaesthetised guinea pigs</u> were pre-treated with the β-adrenergic isoproterenol (i.p.) and subsequently with levosimendan. Left ventricular systolic and diastolic functions and the heart rate were assessed by a non-invasive method (echocardiography). Using this *in vivo* approach we aimed to reveal: a/ whether isoproterenol pre-treaetment modulates the cardiac effects of levosimendan? b/ if

yes, to what degree isoproterenol affects the levosimendan induced positive inotropy?

2) <u>Langendorff-perfused isolated guinea pig hearts</u> were also treated with isoproterenol and subsequently with levosimendan and contractile parameters of the left ventricle were measured in parallel with the phosphorylation levels of myofibrillar proteins (e.g. troponin I). Contractile parameters in this arrangement could be modulated only by isoproterenol and levosimendan. Hence this system was devoid of peripheral vascular effects, systemic reflectoric connections and of the active metabolite (OR-1896) of levosimendan. The Langendorff-preparations also allowed the recording of the changes in intracellular Ca^{2+} concentration during the determination of the dose-effect relationship of the levosimendan on left ventricular function. These experiments provided indirect evidence on the phosphodiesterase inhibitory actions of levosimendan.

3) <u>Permeabilized cardiomyocytes</u> (skinned preparations) were employed to determine the effects of contractile protein phosphorylation ont the levosimendan-evoked Ca^{2+}-sensitisation at constant Ca^{2+} concentrations.

4) <u>Analyses of clinical data</u> allowed the critical evaluation of levosimendan-modulated systemic cardiovascular and cardiac parameters in humans. Based ont he patient charactersitics and the relationships between clinical conditions and pharmacological regimens we tested whether the results of animal experiments can be extrapolated for the humans as well.

METHODS

Echocardiography

Echocardiography was performed with an Acuson Sequoia System (Mountain View, Ca., U.S.A.) in Hartley guinea pigs of either sex (body weight: 450-600 g) following narcosis attained with an intraperitoneal (i.p.) injection of 100 mg·kg^{-1} ketamine. The transducer frequency of the annular array was 7 MHz. Two-dimensional (2D) echocardiography and 2D-guided M-mode imaging were applied. 2D targeted M-mode

studies were performed via the long-axis view of the left ventricle (LV). To assess the systolic and diastolic contractile functions, the velocities of the LV posterior wall motion were determined during contractions (posterior wall contraction velocity; PW-CV) and relaxations (posterior wall relaxation velocity; PW-RV), respectively. The results of the measurements were analysed by two experienced readers over an average of 3 cardiac cycles. All images were recorded on super VHS (sVHS) tapes and on magnetooptical discs.

Langendorff perfusions

Hearts were rapidly excised from Hartley guinea pigs anaesthetised with 30 mg·kg^{-1} sodium pentobarbital and heparinised with 500 U·kg^{-1}. The hearts were immediately cannulated through the aorta and prepared for retrograde perfusion with a modified Krebs buffer. The hearts were initially perfused at a constant aortic pressure (5 kPa) for 20 to 25 minutes in a drip-through mode. The perfusion circuit was then switched to a recirculating system containing 200 cpm·pmol^{-1} [^{32}P]orthophosphate in 120 ml Krebs buffer for 30 minutes. After this labelling period, the circuit was returned to the drip-through mode with nonradioactive buffer for 1 minute. The drug of interest (levosimendan for 5 minutes or isoproterenol for 2 minutes) was administered into the buffer flow line. The hearts were freeze-clamped with a precooled Wollenberger clamp, powdered and stored under liquid nitrogen, as described previously. The heart rate, LV pressure and the derivative of the mechanical function (dP/dt) were monitored continuously, as described previously. dP/dt was derived electronically and stored in a personal computer.

Levosimendan, provided by Orion Pharma (Espoo, Finland), was dissolved in aliquots of isotonic saline or Krebs buffer for the studies with narcotised animals or Langendorff preparations, respectively. For the isolated skinned myocyte study, levosimendan was diluted from a concentrated stock solution (10 mmol·l^{-1} in DMSO). The final concentration of DMSO never exceeded 0.1%. During all animal experiments, institutional guidelines were followed.

Gel electrophoresis and autoradiography

Polyacrylamide gel electrophoresis under denaturing conditions was performed according to Laemmli, using 20% slab gels. After electrophoresis, the gels were fixed, stained with Coomassie blue, destained, sealed in plastic bags and placed into Kodak Lanex regular cassettes loaded with Agfa films for 48-72 hours. The radioactive band corresponding to cTnI was identified and cut from the gel for counting in the scintillation fluid (Scinti Verse, Fisher, St. Louis, MO). Phosphate incorporation was quantified by dividing the amount of ^{32}P incorporated into the proteins by the specific activity of [gamma-^{32}P]ATP determined for each heart, and expressed as picomoles phosphate·milligram protein^{-1}. The specific radioactivity of [gamma-^{32}P]ATP was determined from the specific activity of [^{32}P]phosphocreatine at the end of perfusion.

Force measurement in isolated skinned myocytes

Myocytes were isolated mechanically, as described previously. The compositions of the relaxing and activating solutions used during force measurements were calculated similarly as described by Fabiato and Fabiato. The pCa, i.e., -log[Ca^{2+}], values of the relaxing and activating solutions (pH 7.2) were 10 and 4.75, respectively. Solutions with intermediate [Ca^{2+}] levels were obtained by mixing of the activating and relaxing solutions.

The suspension of myocyte-sized preparations was permeabilised with 0.5% Triton X-100 (Calbiochem, San Diego, USA) (5 minutes). Triton X-100 removed all membranous structures and enabled free diffusion for Ca^{2+}, and thus the study of the Ca^{2+}-sensitising effect of levosimendan under standardised conditions (i.e., in the presence of controlled [Ca^{2+}]$_i$ and sarcomere length). A single myocyte was attached with silicone adhesive (100% silicone, Aquarium sealant, Dow Corning, Midland, USA) to two thin stainless steel needles while viewed by means of an inverted microscope. One needle was attached to a force transducer (SensoNor, Horten, Norway) and the other to an electromagnetic motor (Aurora Scientific Inc., Aurora, Canada), both connected to joystick-controlled micromanipulators. The average sarcomere length was determined by means of a spatial Fourier transform, as described previously, and adjusted to 2.2 μm in the relaxing solution. Solution exchange was

achieved by transferring the myocyte from a small temperature-controlled well (volume 50 μl) containing the relaxing solution to a similar temperature-controlled well containing the activating solution.

The isometric force was measured after the preparation had been transferred to the activating solution. When the peak force was reached, the length of the myocyte was reduced by 20% within 1 millisecond (slack test). As a result of this intervention, the force dropped from the peak level to zero and then started to redevelop. About 3 seconds after the onset of force redevelopment, the myocyte was returned to the relaxing solution, where a slack test with a long slack duration (10 seconds) was performed to assess the passive force level. The active isometric force was calculated by subtracting the passive force from the peak isometric force. Force and length signals were monitored by using an analogue pen-recorder and were stored in a personal computer. The sampling rate during experiments was 20 Hz, while during slack tests it was 1000 Hz. The temperature during force measurements was set to 15 $^{\circ}$C in order to maintain the mechanical stability of the permeabilised myocyte preparations. Force production at the submaximal level of activation (i.e., at pCa 6.2) in the absence or presence of levosimendan was normalised to an interpolated reference force obtained by averaging the two bracketing values of maximal activation (pCa 4.75) at the beginning and at the end of the experiments.

Data analysis

The relation between force (P) and levosimendan concentration ([levo]) was fitted to a modified Hill equation:

$P_{levo} = P_{levo(max)}/(1+([levo]/EC_{50})^{nHill})$

where P_{levo} is the steady-state force at a given concentration of levosimendan, $P_{levo(max)}$ is the steady isometric force at maximal levosimendan effect, the Hill coefficient nHill is a measure of the steepness of the relationship, and EC_{50} is the mid-point of the relation. The results are given throughout as means ± S.E.M. from 4-22 different preparations. Differences were tested by means of Student's unpaired t test at a level of significance of 0.05 ($P < 0.05$).

RESULTS

Echocardiography

The motion velocities of the LV posterior wall during systoles (PW-CV) and diastoles (PW-RV) following application of levosimendan and/or isoproterenol in narcotised guinea pigs demonstrated inotropic and lusitropic responses. The cardiac contractility during this experimental arrangement resulted from the interaction between the cardiac and vascular effects of the chemical agents. Both isoproterenol and levosimendan exerted dose-dependent positive inotropic and lusitropic effects when applied independently. PW-CV and PW-RV increased from a baseline level of 2.08 ± 0.06 cm·s^{-1} and 2.28 ± 0.06 cm·s^{-1} to 2.87 ± 0.09 cm·s^{-1} and 2.99 ± 0.06 cm·s^{-1}, respectively, upon i.p. application of 100 μg·kg^{-1} isoproterenol. These changes were accompanied by an increase in the heart rate from 284 ± 11 to 341 ± 10 beats·min^{-1} (n = 4). Levosimendan also induced marked elevations in both the contraction and relaxation velocities (from 1.96 ± 0.06 cm·s^{-1} and 2.03 ± 0.055 cm·s^{-1} to 2.45 ± 0.075 cm·s^{-1} and 2.38 ± 0.05 cm·s^{-1}, respectively) at a maximal level of stimulation (50 μg·kg^{-1} i.p). The levosimendan-induced maximal change in the heart rate involved an increase from a baseline value of 278 ± 9 to 307 ± 8 beats·min^{-1} (n = 4).

Next, we followed the time courses of the cardiac contractile effects during a period of 30 minutes in two groups of narcotised animals, both treated with a high dose of isoproterenol (50 μg·kg^{-1} i.p.). In the first group of guinea pigs (n=6), isoproterenol was applied alone; while in the second group (n=5), 15 minutes after the isoproterenol injection levosimendan (50 μg·kg^{-1} i.p.) was also injected. The isoproterenol-evoked contractile responses peaked 2 minutes after administration and thereafter remained almost constant for the next 28 minutes. The effect of levosimendan application was judged after 30 minutes by comparing the contractile parameters observed with and without levosimendan. (About 15 minutes was required for the cardiotonic effects of levosimendan to develop when it was applied alone under these experimental conditions.) However, the mean PW-CV and PW-RV values in the two groups of animals did not differ significantly at the end of the experiments.

7

Isolated heart preparations

Next, we set out to assess whether the cardiac effects of levosimendan can be mitigated by isoproterenol pretreatment in isolated hearts. To this end, Langendorff guinea pig hearts were first perfused with a modified Krebs solution that contained isoproterenol (0.1 μM, for 2 minutes) and 15 minutes later they were perfused in the presence of levosimendan (0.3 μM, for 5 minutes). (The concentrations of levosimendan and isoproterenol were selected on the basis of a previous study so as to evoke the maximal effects in this preparation.) Isoproterenol or levosimendan applied alone evoked a maximal increase in $+dP/dt_{max}$ (from a baseline value of 2066 ± 43 mmHg·s^{-1} to 4896 ± 415 mmHg·s^{-1} (n = 8) or from a baseline value of 2050 ± 39 mmHg·s^{-1} to 2624 ± 83 mmHg·s^{-1} (n = 8), respectively) and in $-dP/dt_{max}$ (from a baseline value of 2002 ± 40 mmHg·s^{-1} to 3904 ± 238 mmHg·s^{-1} or from a baseline value of 1990 ± 37 mmHg·s^{-1} to 2269 ± 56 mmHg·s^{-1}, respectively). The isoproterenol-stimulated maximal heart rate corresponded to 273 ± 11 beats·min^{-1}, which developed from a baseline value of 172 ± 16 beats·min^{-1}. In comparison, the levosimendan-stimulated maximal heart rate was 201 ± 3 beats·min^{-1}, which developed from a baseline value of 175 ± 4 beats·min^{-1}. In contrast to the narcotised animals, the isoproterenol-induced contractile effects could be washed out rapidly: they had vanished 15 minutes after isoproterenol application in the Langendorff-perfused hearts. However, the contractile parameters were not increased significantly by levosimendan administration 15 minutes after isoproterenol application. To estimate the phosphorylation levels of the contractile proteins in parallel with the combined isoproterenol and subsequent levosimendan treatment, ^{32}P incorporation into cTnI was determined in the Langendorff-perfused hearts (n = 4). Isoproterenol induced a major elevation in the level of cTnI phosphorylation and this parameter remained significantly elevated during the time when levosimendan was administered.

Isolated cardiomyocyte studies

The interaction between levosimendan and the β-adrenergic signalling was further investigated in skinned myocytes (n = 22 from 5 guinea pig hearts). This experimental approach allowed the comparison of force values at identical levels of [Ca^{2+}] and protein phosphorylation. Maximal Ca^{2+}-activated force (measured at pCa 4.75) was 22 ± 2 kN·m^{-2} in the myocytes exposed only to levosimendan (n = 11) and it was 22 ± 3 kN·m^{-2} (P<0.05) in the myocytes (n = 11) treated first with protein kinase A and thereafter with levosimendan. Previous experience led to the choice of a single submaximal [Ca^{2+}] (pCa 6.2 in this case) for characterisation of the Ca^{2+}-sensitising effect of levosimendan. At pCa 6.2, the isometric force in the absence of levosimendan was 13 ± 1% of the maximal isometric force and levosimendan induced a dose-dependent increase from this force level. The maximal increase in force production accounted for an added 51 ± 5%. However, when the recordings were repeated following 40 minutes of protein kinase A incubation (100 U·ml^{-1}), the application of increasing concentrations of levosimendan was not accompanied by significant increases in isometric force production. This effect could not be explained by a parallel change in the baseline force (in the absence of levosimendan) at pCa 6.2, because it was also 13 ± 1% of the maximal isometric force following protein kinase A treatment.

Investigations during human heart failure

The clinical efficacy of levosimendan was compared with a conventional positive inotropic egant (dobutamin) in different patient groups (acut exacerbation of chronic heart failure, global stunning following cardiac surgery, end-stage heart failure). In this, so called LIDO study 203 patients were randomized. Our insitution contributed with 10 patients to the total patient population. According to the results of the LIDO investigation levosimendan has a favourable haemodynamic profile and is well tolerated by the patients. Levosimendan significantly decreased the mortality at 30 days and half year. Subgroup analysis of the LIDO patients revealed an advantagoues effect of chronic β-blocking therapy on the hamodynamic indices of levosimendan (i.e. cadiac output, capillary wedge pressure).

DISCUSSION

This study has revealed that in the presence of intensive β-mimetic stimulation the cardiotonic effects of levosimendan are attenuated. The negative interaction between the action of isoproterenol and levosimendan could be demonstrated in whole animals as well as in Langendorff-perfused hearts, but it was also present in skinned myocytes This identified the contractile filaments as potential mediators of this relationship. The reduction in the Ca^{2+}-senstitising potential of levosimendan was paralleled by an increase in the level of cTnI phosphorylation, suggesting that the phosphorylation status of the contractile proteins is an important determinant of levosimendan-mediated Ca^{2+}-sensitisation.

The results of echocardiographic examinations identified levosimendan as a potent cardiotonic agent in narcotised guinea pigs. Both the systolic and the diastolic functions underwent dose-dependent enhancements in response to levosimendan administration. In narcotised guinea pigs, the levosimendan-induced maximal increases in the systolic and diastolic functions were comparable to the maximal effects induced by isoproterenol alone. In Langendorff-perfused hearts, however, the maximal effects of levosimendan on $+dP/dt_{max}$ and $-dP/dt_{max}$ were less pronounced when compared to those induced by isoproterenol alone. This suggests that the contractile function of the heart benefits more from levosimendan application when the entire cardiovascular system is exposed to this agent and implies that Ca^{2+}-sensitised contractile filaments promote the cardiac function to a larger extent in a haemodynamic background modulated by the additional effects of levosimendan. This may involve activation of the ATP-dependent K^+ channels in the vascular smooth muscle cells, with consequent vasodilatation.

In narcotised guinea pigs, the contraction velocity was enhanced at lower doses of levosimendan than was the relaxation velocity. This is most probably a consequence of a pure Ca^{2+}-sensitising effect at lower plasma levels of the drug in the myocardial cells. At the highest concentration of levosimendan, an additional phosphodiesterase-inhibitory effect cannot be excluded. In agreement with this assumption, we observed

a pronounced increase in lusitropy (enhancement of the relaxation velocities in narcotised guinea pigs, and an increase in $-dP/dt_{max}$ in Langendorff hearts) at the highest doses of levosimendan. The pure Ca^{2+}-sensitising effect of levosimendan was demonstrated in isolated skinned cardiomyocytes, where Ca^{2+} sequestration and release were prevented by the elimination of the membranous structures. Additionally, the $[Ca^{2+}]$ in the myofibrillar space was maintained at a steady level by the Ca^{2+} buffer applied during the individual activations. Therefore, neither inhibition of phosphodiesterases nor ATP-dependent K^+ channel activation could influence force generation in the skinned myocytes. In accordance with previous observations, levosimendan was able to increase the force at a submaximal level of activation in consequence of its Ca^{2+}-sensitising potential in this preparation. The calculated EC_{50} value for this effect was notably low (5 ± 3 nmol·l^{-1}), which lends further support to the suggested mechanism of action of levosimendan as a Ca^{2+}-sensitiser at low plasma concentrations.

Intensive isoproterenol stimulation prevented the development of the cardiotonic effects of levosimendan in narcotised guinea pigs and in Langendorff hearts. In the Langendorff hearts, the isoproterenol-evoked increases in the contractile parameters had disappeared, and the parameters had returned to the baseline levels before the administration of levosimendan. Nonetheless, no significant effect in response to levosimendan administration could be demonstrated in this phase of the experiments. This suggested that not the contractile reserve, but rather a decrease in the sensitivity for levosimendan, was responsible for the negative interaction following β-stimulation. Isolated skinned myocytes allow direct modulation of the phosphorylation levels of the myofilaments and selective characterisation of the consequences. Previous studies have demonstrated that incubation of skinned myocytes in the presence of the catalytic subunit of protein kinase A is an effective method of inducing marked elevations in the levels of phosphorylation of myofibrillar proteins. Following protein kinase A exposure, levosimendan did not increase the force in isolated guinea pig myocytes. The data on ^{32}P incorporation into the cTnI of Langendorff hearts were in accord with this observation. Hence, as suggested earlier,

protein kinase A-mediated cTnI phosphorylation may be involved in the reduction of the myofilament sensitivity to levosimendan.

In the failing human myocardium, the β-mimetic responsiveness is reduced, the level of cTnI phosphorylation is presumed to be decreased and the Ca^{2+} sensitivtiy of force production is thought to be increased. Additionally, the amplitude of the $[Ca^{2+}]_i$ transient in the chronically remodeled heart is diminished. On the other hand, the binding of levosimendan to cTnC, and therefore, the levosimendan-induced positive inotropic action, are both Ca^{2+}-dependent. It has been suggested that this Ca^{2+} dependence explains why an increase in the amplitude of the cytosolic Ca^{2+} transient (induced either by isoproterenol or by elevation of the extracellular $[Ca^{2+}]$) augments the Ca^{2+}-sensitising effect of levosimendan in muscle strip preparations from the failing human heart. On the basis of our findings, it may also be argued that the downgraded β-signalling system would probably not allow isoproterenol stimulation to increase the contractile protein phosphorylation to levels high enough to oppose the cardiotonic effects of levosimendan in failing human heart preparations.

In summary, the Ca^{2+}-sensitising potential of levosimendan can be negatively influenced by stimulation of the β-adrenergic system. However, the efficiency of levosimendan-induced Ca^{2+}-sensitisation may depend on the interplay between the levels of activating $[Ca^{2+}]_i$ and of contractile protein phosphorylation at the subcellular level. Ca^{2+} handling and β-adrenergic signalling are both impaired during advanced chronic heart failure. This may theoretically generate a more favourable background for the interactions between the β-mimetic agents and levosimendan in the failing human heart as compared with the healthy myocardium.

SUMMARY

Echocardiographic examinations of the left ventricle revealed the dose-dependent positive inotropic effect of levosimendan in anaesthetized guinea pigs. This positive inotropic effect could be, however, suspended by isoproterenol pre-treatment.

Levosimendan evoked a significant increase in left ventricular contractile function (assessed by $+dP/dt_{max}$) in Langendorff-perfused isolated guinea pig hearts. Isoproterenol pre-treatment, however, diminished the levosimendan-evoked positive inotropic effect in the isolated guinea pig hearts.

An isolated myocyte study was performed to investigate the relationship between levosimendan induced Ca^{2+}-sensitisation and troponin I phosphorylation. The advantage of these permeabilized myocyte preparations is that complex haemodynamic effects (variations in pre- and afterload, changes in heart rate) are avoided during myofibrillar force generation. Our results indicated that levosimendan possessed a dose-dependent Ca^{2+}-sensitising effect in isolated myocytes. This effect was most prominent at submaximal levels of Ca^{2+}-activation. Proteinkinase A pre-treatment (in the presence of ATP) that induced protein phosphorylation, however, prevented the development of Ca^{2+}-sensitisation.

Results of our clinical experience and of other investigators suggested that levosimendan is a potent positive inotropic agent without major side effects. Analysis of the haemodynamic parameters of our patients enrolled for the LIDO study suggested that chronic β-blocking therapy does not limit the haemodynamic effects of levosimendan (on the cardiac output and pulmonary capillary wedge pressure), on the contrary, it may even improve it. Hence, we hypothesise, that the therapeutic efficacy of levosimendan is anti-paralleled by the phosphorylation level of troponin I. Based on this assumption, the analysis on the relationship between chronic β-blocking therapy and levosimendan efficacy has been extended for the entire patient group of the LIDO study and similar results were obtained.

In extenso papers in journals and book chapter supporting the Ph.D. theses

1. **Bódi A**, Kristóf É, Kiss É, Czuriga I, Papp Gy, Édes I. (1995): A Ca^{2+}-érzékenyítők hatása a bal kamra funkcióra és a myocardium fehérje foszforilációs rendszerére. *Cardiol. Hung. 24:7-12.*

2. Édes I, Kristóf É, **Bódi A.** (1997): A krónikus szívelégtelenség kialakulásának patomechnizmusa. *Magyar Belorvosi Archivum 50:515-518.*

3. Kristóf É, Szigeti G, Papp Z, **Bódi A**, Facskó A, Papp JG, Kovács L, Kranias GE, Édes I. (1998): Cardiac responses to calcium sensitizers: effects on left ventricular function cyclic AMP levels, protein phosphorylation and myoplassmic calcium concentration. *Ann. N.Y. Acad. Sci. 853:316-319.* **IF: 0,959**

4. Édes I, Kristóf É, **Bódi A.**: A krónikus szívelégtelenség kialakulásának cellularis, molekuláris mechanizmusa. Fejezet a Kardiologia című szakkönyvből, Szerkesztő: Préda I. in press.

5. **Bódi A**, Szilágyi S, Édes I, Papp Z. (2003): The cardiotomic effects of levosimendan in guinea pig hearts are modulated by β-adrenergic stimulation. *Gen. Physiol. Biophys. 22:313-327.* **IF: 0,719**

Phase III trial supporting the Ph.D. theses

6. Follath F. et al., and LIDO investigators incl. **Bódi A.** (2002): Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. *Lancet 360:196-202.* **IF: 15,397**

Additional *in extenso* papers in journals

7. Vaszily M, Hejjel L, Szerafin T, **Bódi A**, Hermann K, Péterffy Á. (1997): Dynamicus cardiomyoplastica II. Saját tapasztalataink. *Cardiol. Hung. 3:115-120.*

8. Kristóf É, Szigeti Gy, Papp Z, **Bódi A**, Ball AN, Walsh RA, Édes I. (1999): The effects of levosimendan on the left ventricular function and protein phosphorylation in postischemic guinea pig hearts. *Bas. Res. Cardiol. 94:223-230.* **IF: 1,148**

9. Varga E, **Bódi A**, Ferdinandy P, Droy-Lefaix M, Blasing IE, Tosaki A. (1999): The protective effects of EGb 761 in isolated ischemic/ reperfused rat hearts: A link between cardiac function and nitric oxide production. *J. Cardiovasc. Pharmacol. 34:711-717.* **IF: 1,989**

10. Nagy Z, **Bodi A**, Vaszily M, Szerafin T, Horvath A, Jagamos E, Horvath G, Peterffy A. (1999): A mitralis insufficientia műtéti kezelése annuloplasticás öltéssel. *Orv. Hetil.* **140:285-289.**

11. Nagy ZL, **Bodi A**, Vaszily M, Szerafin T, Horvath A, Peterffy A. (2000) Five-year experience with a suture annuloplasty for mitral valve repair. *Scand. Cardiovasc. J.* **34:528-532.** **IF: 0,508**

12. Nagy Z, **Bodi A**, Vaszily M, Szerafin T, Galajda Z, Len A, Peterffy A. (2002) A Pericarbon stent-nélküli műbillentyűvel kapcsolatos két éves magyarországi tapasztalatok. *Orv. Hetil.* **143:2337-2341.**

Abstracts in journals supporting the Ph.D. theses

13. Édes I, **Bódi A**, Kiss É, Tálosi L, Papp Gy. (1995): Effects of levosimendan on sarcoplasmic reticular function in guinea pig hearts. *Cardiol. Hung.* ***Suppl.1:***38.

14. Édes I, Kristóf É, **Bódi A**, Kiss É. (1996): Effects of calcium sensitizers on left ventricular function and myocardial protein phosphorylation. *J. Mol. Cell Cardiol.* **28:A142.**

15. **Bódi A**, Kristóf É, Kruzsicz V, Hegedűs I, Édes I. (1998): Effects of levosimendan on left ventricular function in guinea pigs – an echocardiographic study. *Cardiol. Hung.* ***Suppl.1:65.***

16. Kristóf É, Szigeti Gy, Papp Z, **Bódi A**, Papp Gy, Kovács L, Édes I. (1998): Cardiac responses to calcium sensitizers: effects on left ventricular function and myoplasmic calcium concentration. *Cardiol. Hung.* ***Suppl.1:66.***

17. Kristóf É, **Bódi A**, Ball AN, Walsh RA, Édes I. (1999): The effects of levosimendan on the postischaemic myocardium. *J. Card. Fail.* *5/3****Suppl.1***:A228.

18. **Bódi A**, Szilágyi S, Papp Z, Édes I. (2003): Interaction between beta-adrenergic stimulation and levosimendan induced positive inotropy in guinea pig hearts. *Cardiol. Hung.* ***Suppl.2:21.***

19. **Bódi A**, Szilágyi S, Papp Z, Édes I. (2003): The cardiotonic effects of levosimendan in guinea pig hearts are modulated by beta-adrenergic stimulation *Bas. Res. Cardiol.* **98**:A42.

20. **Bódi A**, Szilágyi S, Papp Z, Édes I. (2003): Cardiac β-adrenergic signalization and levosimendan. *"11th Alpe Adria Cardiology Meeting" kongresszusi kiadványa:36.*

Additional abstracts in journals

21. Vaszily M, **Bódi A**, Polgár P, Szerafin T, Péterffy Á. (1995): Az első dynamicus cardiomyoplastica műtétek során szerzett tapasztalataink. *Cardiol. Hung. Suppl.24:92.*

22. Vaszily M, **Bódi A**, Szerafin T, Szabó Z, Péterffy Á. (1995): Clinical experience with dynamic cardiomyoplasty in Hungary. *Cardiol. Hung. Suppl.3:43.*

23. Barta J, Tóth A, Édes I, Vaszily M, Kristóf É, **Bódi A**, Papp Z. (2001): Calpain-I degrades desmin more effectively than troponin I in human myocardium. *J. Mol. Cell. Cardiol. 33:A8.*